Advertisement

Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation

Published:March 08, 2021DOI:https://doi.org/10.1016/j.ejim.2021.02.011

      Highlights

      • GDF-15 is a promising biomarker in atrial fibrillation
      • It predicts all-cause mortality in a real-world cohort
      • GDF-15 is independently associated with major adverse cardiac events
      • Repeated GDF-15 measurements showed stable levels over time
      • The ABC-death risk score was validated and showed good discriminative performance

      Abstract

      Background: Growth-differentiation factor-15 (GDF-15) has recently been described as a potential biomarker for predicting risk of mortality and cardiovascular events in patients with atrial fibrillation (AF) but requires validation in clinical practice.
      Methods: The study population consisted of 362 patients (mean age: 71 years, 37% women) with non-valvular AF included in a prospective cohort study. Relationship of GDF-15 with all-cause mortality and major adverse cardiac events (MACE) was analyzed using Cox regression. Survival analysis stratified by GDF-15 was based on national death records, while MACE was recorded at personal follow-up. Further, we evaluated the recently developed GDF-15 based prognostic score towards prediction of all-cause mortality (ABC-death score).
      Results: Over a median observation period of 4.3 years, 81 (23.3%) patients died, and over a median personal follow-up of 316 days 47 MACE occurred. GDF-15 was independently associated with all-cause mortality (adjusted HR per double increase 2.33, 95%CI 1.74-3.13) and MACE (adjusted HR per double increase 2.33, 95%CI 1.60-3.39). GDF-15 levels, measured at follow-up, were similarly associated with mortality, and longitudinal measurements of GDF-15 did not significantly differ. Six-year survival probability of patients above vs. below the median GDF-15 level was 44% (95%CI 34-57) and 84% (95%CI 76-93), respectively. The ABC-death score revealed a C-statistic of 0.80.
      Conclusion: GDF-15 predicts risk of all-cause mortality and MACE in patients with non-valvular AF. Further, the ABC-death score showed good predictive accuracy in a “real-world” cohort. Therefore, introduction of GDF-15 into clinical practice would enhance risk prediction of morbidity and mortality in AF patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gage BF
        • van Walraven C
        • Pearce L
        • Hart RG
        • Koudstaal PJ
        • Boode BS
        • Petersen P
        Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
        Circulation. 2004; 110: 2287-2292
        • Chang G
        • Xie Q
        • Ma L
        • Hu K
        • Zhang Z
        • Mu G
        • Cui Y.
        Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis.
        Journal of Thrombosis and Haemostasis. 2020; 18: 791-801
        • Chen JY
        • Zhang AD
        • Lu HY
        • Guo J
        • Wang FF
        • Li ZC.
        CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis.
        J Geriatr Cardiol. 2013; 10: 258-266
        • Hijazi Z
        • Lindbäck J
        • Alexander JH
        • Hanna M
        • Held C
        • Hylek EM
        • Lopes RD
        • Oldgren J
        • Siegbahn A
        • Stewart RAH
        • White HD
        • Granger CB
        • Wallentin L
        • t ARISTOTLE
        • Investigators S
        The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation.
        European Heart Journal. 2016; 37: 1582-1590
        • Hijazi Z
        • Oldgren J
        • Lindback J
        • Alexander JH
        • Connolly SJ
        • Eikelboom JW
        • Ezekowitz MD
        • Held C
        • Hylek EM
        • Lopes RD
        • Siegbahn A
        • Yusuf S
        • Granger CB
        • Wallentin L.
        The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
        Lancet (London, England). 2016; 387: 2302-2311
        • Hijazi Z
        • Oldgren J
        • Lindbäck J
        • Alexander JH
        • Connolly SJ
        • Eikelboom JW
        • Ezekowitz MD
        • Held C
        • Hylek EM
        • Lopes RD
        • Yusuf S
        • Granger CB
        • Siegbahn A
        • Wallentin L.
        A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
        Eur Heart J. 2018; 39: 477-485
        • Wollert KC
        • Kempf T
        • Wallentin L.
        Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.
        Clinical chemistry. 2017; 63: 140-151
        • Wollert KC
        • Kempf T.
        Growth Differentiation Factor 15 in Heart Failure: An Update.
        Current Heart Failure Reports. 2012; 9: 337-345
        • Kempf T
        • Wollert KC.
        Growth Differentiation Factor-15: a New Biomarker in Cardiovascular Disease.
        Herz. 2009; 34: 594-599
        • Wallentin L
        • Zethelius B
        • Berglund L
        • Eggers KM
        • Lind L
        • Lindahl B
        • Wollert KC
        • Siegbahn A.
        GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men.
        PloS one. 2013; 8 (e78797-e78797)
        • Kempf T
        • Björklund E
        • Olofsson S
        • Lindahl B
        • Allhoff T
        • Peter T
        • Tongers J
        • Wollert KC
        • Wallentin L.
        Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction.
        Eur Heart J. 2007; 28: 2858-2865
        • Wallentin L
        • Hijazi Z
        • Andersson U
        • Alexander JH
        • De Caterina R
        • Hanna M
        • Horowitz JD
        • Hylek EM
        • Lopes RD
        • Asberg S
        • Granger CB
        • Siegbahn A.
        Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
        Circulation. 2014; 130: 1847-1858
        • Berg DD
        • Ruff CT
        • Jarolim P
        • Giugliano RP
        • Nordio F
        • Lanz HJ
        • Mercuri MF
        • Antman EM
        • Braunwald E
        • Morrow DA.
        Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
        Circulation. 2019; 139: 760-771
        • Marín F
        • Roldán V.
        GDF-15 and risk stratification in atrial fibrillation.
        Nature Reviews Cardiology. 2015; 12: 8-9
        • Königsbrügge O
        • Simon A
        • Domanovits H
        • Pabinger I
        • Ay C.
        Thromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.
        BMC Cardiovasc Disord. 2016; 16: 254
        • Aldo P
        • Marusov G
        • Svancara D
        • David J
        • Mor G.
        Simple Plex: A Novel Multi-Analyte, Automated Microfluidic Immunoassay Platform for the Detection of Human and Mouse Cytokines and Chemokines.
        Am J Reprod Immunol. 2016; 75: 678-693
        • Weide B
        • Schäfer T
        • Martens A
        • Kuzkina A
        • Uder L
        • Noor S
        • Garbe C
        • Harter PN
        • Mittelbronn M
        • Wischhusen J.
        High GDF-15 Serum Levels Independently Correlate with Poorer Overall Survival of Patients with Tumor-Free Stage III and Unresectable Stage IV Melanoma.
        J Invest Dermatol. 2016; 136: 2444-2452
        • Daniels LB
        • Clopton P
        • Laughlin GA
        • Maisel AS
        • Barrett-Connor E.
        Growth-Differentiation Factor-15 Is a Robust, Independent Predictor of 11-Year Mortality Risk in Community-Dwelling Older Adults.
        Circulation. 2011; 123: 2101-2110
        • Wallentin L
        • Zethelius B
        • Berglund L
        • Eggers KM
        • Lind L
        • Lindahl B
        • Wollert KC
        • Siegbahn A.
        GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men.
        PLOS ONE. 2013; 8: e78797
        • Rohatgi A
        • Patel P
        • Das SR
        • Ayers CR
        • Khera A
        • Martinez-Rumayor A
        • Berry JD
        • McGuire DK
        • de Lemos JA.
        Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study.
        Clinical chemistry. 2012; 58: 172-182
        • Wollert KC
        • Kempf T
        • Peter T
        • Olofsson S
        • James S
        • Johnston N
        • Lindahl B
        • Horn-Wichmann R
        • Brabant G
        • Simoons ML
        • Armstrong PW
        • Califf RM
        • Drexler H
        • Wallentin L.
        Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
        Circulation. 2007; 115: 962-971
        • Wiklund FE
        • Bennet AM
        • Magnusson PK
        • Eriksson UK
        • Lindmark F
        • Wu L
        • Yaghoutyfam N
        • Marquis CP
        • Stattin P
        • Pedersen NL
        • Adami HO
        • Grönberg H
        • Breit SN
        • Brown DA.
        Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality.
        Aging Cell. 2010; 9: 1057-1064
        • Schopfer DW
        • Ku IA
        • Regan M
        • Whooley MA.
        Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study).
        Am Heart J. 2014; 167 (186-192.e181)
        • Wollert KC
        • Kempf T
        • Wallentin L.
        Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.
        Clinical chemistry. 2017; 63: 140-151
        • Kempf T
        • Sinning JM
        • Quint A
        • Bickel C
        • Sinning C
        • Wild PS
        • Schnabel R
        • Lubos E
        • Rupprecht HJ
        • Münzel T
        • Drexler H
        • Blankenberg S
        • Wollert KC.
        Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study.
        Circ Cardiovasc Genet. 2009; 2: 286-292
        • Dallmeier D
        • Brenner H
        • Mons U
        • Rottbauer W
        • Koenig W
        • Rothenbacher D.
        Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study.
        Clinical chemistry. 2016; 62: 982-992
        • Hagström E
        • Held C
        • Stewart RA
        • Aylward PE
        • Budaj A
        • Cannon CP
        • Koenig W
        • Krug-Gourley S
        • Mohler 3rd, ER
        • Steg PG
        • Tarka E
        • Östlund O
        • White HD
        • Siegbahn A
        • Wallentin L.
        Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
        Clinical chemistry. 2017; 63: 325-333
        • Khan SQ
        • Ng K
        • Dhillon O
        • Kelly D
        • Quinn P
        • Squire IB
        • Davies JE
        • Ng LL.
        Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
        Eur Heart J. 2009; 30: 1057-1065
        • Bonaca MP
        • Morrow DA
        • Braunwald E
        • Cannon CP
        • Jiang S
        • Breher S
        • Sabatine MS
        • Kempf T
        • Wallentin L
        • Wollert KC.
        Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.
        Arterioscler Thromb Vasc Biol. 2011; 31: 203-210
        • Hagström E
        • James SK
        • Bertilsson M
        • Becker RC
        • Himmelmann A
        • Husted S
        • Katus HA
        • Steg PG
        • Storey RF
        • Siegbahn A
        • Wallentin L.
        Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
        Eur Heart J. 2016; 37: 1325-1333
        • Anand IS
        • Kempf T
        • Rector TS
        • Tapken H
        • Allhoff T
        • Jantzen F
        • Kuskowski M
        • Cohn JN
        • Drexler H
        • Wollert KC.
        Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
        Circulation. 2010; 122: 1387-1395
        • Hijazi Z
        • Oldgren J
        • Andersson U
        • Connolly SJ
        • Eikelboom JW
        • Ezekowitz MD
        • Reilly PA
        • Yusuf S
        • Siegbahn A
        • Wallentin L.
        Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
        American Heart Journal. 2017; 190: 94-103
        • Hagström E
        • James SK
        • Bertilsson M
        • Becker RC
        • Himmelmann A
        • Husted S
        • Katus HA
        • Steg PG
        • Storey RF
        • Siegbahn A
        • Wallentin L
        • ftP Investigators
        Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
        European Heart Journal. 2015; 37: 1325-1333
        • Kempf T
        • Horn-Wichmann R
        • Brabant G
        • Peter T
        • Allhoff T
        • Klein G
        • Drexler H
        • Johnston N
        • Wallentin L
        • Wollert KC.
        Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay.
        Clinical chemistry. 2007; 53: 284-291
        • Anand IS
        • Kempf T
        • Rector TS
        • Tapken H
        • Allhoff T
        • Jantzen F
        • Kuskowski M
        • Cohn JN
        • Drexler H
        • Wollert KC.
        Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure.
        Circulation. 2010; 122: 1387-1395
        • Lind L
        • Wallentin L
        • Kempf T
        • Tapken H
        • Quint A
        • Lindahl B
        • Olofsson S
        • Venge P
        • Larsson A
        • Hulthe J
        • Elmgren A
        • Wollert KC.
        Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study.
        European Heart Journal. 2009; 30: 2346-2353
        • Granger CB
        • Alexander JH
        • McMurray JJV
        • Lopes RD
        • Hylek EM
        • Hanna M
        • Al-Khalidi HR
        • Ansell J
        • Atar D
        • Avezum A
        • Bahit MC
        • Diaz R
        • Easton JD
        • Ezekowitz JA
        • Flaker G
        • Garcia D
        • Geraldes M
        • Gersh BJ
        • Golitsyn S
        • Goto S
        • Hermosillo AG
        • Hohnloser SH
        • Horowitz J
        • Mohan P
        • Jansky P
        • Lewis BS
        • Lopez-Sendon JL
        • Pais P
        • Parkhomenko A
        • Verheugt FWA
        • Zhu J
        • Wallentin L
        Apixaban versus Warfarin in Patients with Atrial Fibrillation.
        New England Journal of Medicine. 2011; 365: 981-992
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • Eikelboom J
        • Oldgren J
        • Parekh A
        • Pogue J
        • Reilly PA
        • Themeles E
        • Varrone J
        • Wang S
        • Alings M
        • Xavier D
        • Zhu J
        • Diaz R
        • Lewis BS
        • Darius H
        • Diener H-C
        • Joyner CD
        • Wallentin L.
        Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
        New England Journal of Medicine. 2009; 361: 1139-1151